Weekly Recap | ADPT.US -0.33%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.ADPT.US slipped 0.33% this week to close at $24.20, outperforming the S&P 500, which fell 0.8%. Trading was range-bound: after opening at $23.98 on Tuesday, the stock edged higher through midweek, dipped to $23.53 on Thursday, and then faded from a Friday high of $24.79 to end nearly flat versus the prior Friday. There was no major catalyst, and average daily volume of about 1.19m shares sat well below the 60-day median of roughly 2.39m.
The Week
ADPT.US slipped 0.33% this week to close at $24.20, outperforming the S&P 500, which fell 0.8%. Trading was range-bound: after opening at $23.98 on Tuesday, the stock edged higher through midweek, dipped to $23.53 on Thursday, and then faded from a Friday high of $24.79 to end nearly flat versus the prior Friday. There was no major catalyst, and average daily volume of about 1.19m shares sat well below the 60-day median of roughly 2.39m.
Analyst Ratings
Eight firms cover ADPT.US: five rate it a buy, two overweight, and one hold, with no underweight or sell ratings. The consensus rating is buy, with a consensus target of $25.07, about 3.6% above the latest price. Targets range from $21.00 to $28.00, a roughly $7 spread that points to moderate dispersion. The stock ranks 27th out of 54 names in the life-science tools and services industry.
The Week Ahead
On the macro front, the New York Fed manufacturing index lands Tuesday (prior 20.6, consensus 14.75), followed by Wednesday’s retail sales figures (prior -0.6, consensus 0.9), which could shift risk appetite for biotech. No company-specific earnings are scheduled, so the watch items are whether this week’s light volume persists and how price behaves around the $25 level and the 20-day moving average.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.